Obviousness Analysis Trends In Pharma Patent Cases
By Joseph Bennett-Paris and Roshan Shrestha (May 3, 2019, 2:51 PM EDT) -- Recent decisions from the U.S. Court of Appeals for the Federal Circuit highlight the uphill battle patent challengers face in seeking invalidation of pharmaceutical patents.
The Federal Circuit applies at least two different standards for determining obviousness, one for pharmaceutical patent claims directed to specific compounds or a genus of compounds, and a second when the claims are directed to a pharmaceutical formulations. Although the former standard, often called the "lead compound analysis" has been particularly weighted in favor of upholding patentability while the latter is considered to be more "relaxed," the bar appears to be shifting further in favor of...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!